



From experience to insight.

Company Overview

Type:	Biotech
Founded:	Cambridge, MA, USA 2008
Headquarters:	One Kendall Square Cambridge, MA, USA
Area served:	Worldwide
Key people:	Ian Ratcliffe, CEO; Joe Gentile, COO; Bryan Roberts, VP
Employees:	40+ worldwide
Website:	www.stemgent.com

Stemgent, Inc. is engaged in working alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions for the advancement of stem cell research. Our mission is to help simplify and support cellular reprogramming research by producing products being designed by leading stem cell researchers worldwide. Our scientific development sites are located in both Cambridge, Massachusetts and San Diego, California.

COMPANY HIGHLIGHTS

Experts in Cellular Reprogramming: Our reagent product portfolio is among the most advanced in stem cell research. Our products are stem cell-qualified and include the most comprehensive set of tools for generating iPS cells as well as cell lines, media, small molecules and antibodies. We are also the sole provider of the WIT media system for breast cancer research developed at the Whitehead Institute.

Leading iPS Cell Culture Training Courses: Our mouse and human reprogramming courses at Stemgent cover all essential protocols for lentiviral reprogramming and ES/iPS cell culture techniques in a hands-on laboratory environment. Our courses have been designed to enable researchers to easily transfer these techniques to reprogramming experiments carried out in their own labs.

Pioneers in Stem Cell Discovery: Our Scientific Advisory Board have published many of the discoveries that drive stem cell science today. Dr. Rudolf Jaenisch, Dr. Doug Melton, Dr. James Thomson, and Dr. Sheng Ding are widely regarded as among the foremost experts in stem cell biology. Visit stemgent.com for a full listing of our SAB members.

MILESTONES

February 2008: Stemgent opens its first office in Cambridge, MA, the following April, the San Diego, CA facility opens. The company launches first set of research tools focused on cellular reprogramming.

November 2009: Stemgent and Sigma Aldrich signed a worldwide distribution agreement to offer lentivirus-based delivery systems for the generation of induced pluripotent stem cells (iPSC). Stemgent is voted as one of the top 25 up and coming biotech companies.

January 2010: Stemgent launches custom cell line generation services providing companies iPS cell line generation engineer reporter cell lines, and characterized pluripotent iPS or ES cells.

March 2010: Stemgent launches Ubiquigent Ltd, a company based in Dundee, Scotland. Ubiquigent produces technology that focuses on the biology of the ubiquitin proteasome pathway. Housed by the Scottish Institute for Cell Signalling (SCILLS) at the University of Dundee and is co-founded by Professor Sir Philip Cohen.

May 2010: Stemgent and Miltenyi Biotec announced a strategic collaboration for co-development and commercialization of stem cell research products. Miltenyi Biotec supports worldwide marketing and sales of Stemgent's current product portfolio.

September 2010: Stemgent held the first commercially available iPS training course at the National Institute of Health facility. In December 2010 Stemgent held the first human iPS training course in San Diego, CA.



www.stemgent.com